PART ONE
General Cytology
10. Stewart BW, Kleihues P (eds)
World Can-
cer Report2003.
Lyon: IARC Press, 2003.
11. Walboomers JM, Jacobs MV, Manos MM,
et al. Human papillomavirus is a neces-
sary cause of invasive cancer worldwide.
J Pathol
1999;189:12-19.
12. International Agency for Research on
Cancer.
IARC Handbooks of Cancer Preven-
tion: Cervical Cancer Screening.
Lyon:
IARC, 2005: 1-57.
13. Richart RM.
Task Force Two: Reasons for
Regional I Differences in Prevalence of
Cervical Lesions.
Chicago: International
Conference on the Fight Against Cervical
Cancer, 2000.
14. Waddell C. Glandular prediction: the
pride and the prejudice.
Cytopathology
2004;15:177-180.
15. Koss LG. The Papanicolaou test for cervi-
cal cancer detection: a triumph and a
tragedy.
JAMA
1989;261:737-743.
16. Parkin DM, Bray F. The burden of HPV-
related cancers.
Vaccine
2006;24(Suppl 3):
11-25.
17. Miller AB, Anderson G, Brisson J, et al.
Report of a National Workshop on
Screening for Cancer of the Cervix.
Can
Med Assoc J
1991;145(10):1301-1325.
18. Denny L. The prevention of cervical
cancer in developing countries.
BJOG
2005;112:1204-1212.
19. Johannesson G, Geirsson G, Day N.
The effect of mass screening in Iceland,
1965-1974, on the incidence and mortal-
ity of cervical carcinoma.
Int J Cancer
1978;21:418-425.
20. Hakama M. Trends in the incidence of
cervical cancer in the Nordic countries.
In:Magnus K (ed)
Trends in Cancer
Incidence.
New York: Hemisphere Press,
1982: 279-292.
21. Laara E, Day NE, Hakama M. Trends
in mortality from cervical cancer in
the Nordic countries: association with
organised screening programmes.
Lancet
1987;1:1247-1249.
22. Anderson GH, Benedet JL, LeRiche JC,
et al. Invasive cancer of the cervix in Brit-
ish Columbia: A review of demographic
and screening histories of 437 cases seen
from 1985-1988.
Obstet Gynecol
1992;80(1):1-4.
23. Krane JF, Granter SR, Trask CE, et al.
Papanicolaou smear sensitivity for the
detection of adenocarcinoma of the cervix:
a study of 49 cases.
Cancer
2001;93:8-15.
24. International Agency for Research on
Cancer (IARC). IARC confirms efficacy
of cervix cancer screening for women
25-65 in reducing mortality. Press release
no. 151. Lyon; 2004 [cited 2004 May 3].
Acessed on 2007 Mar 31 Available from:
Summary.pdf
25. Fahey MT, Irwig L, Macaskill P. Meta-
analysis of Pap test accuracy.
Am J Epide-
miol
1995;141:680-689.
26. Nanda K, McCrory DC, Myers ER,
et al. Accuracy of the Papanicolaou test
in screening for and follow-up of cervical
cytologic abnormalities: a systematic
review.
Ann Intern Med
2000;132:810-819.
27. Parikh S, Brennan P, Boffetta P. Meta-
analysis of social inequality and the
risk of cervical cancer.
Int J Cancer
2003;105:687-691.
28. Miller AB. Quality assurance in
screening strategies. Review.
Virus Res
2002;89(2):295-299.
29. Suba EJ. Crossing the quality chasm: a
requirement for successful cervical cancer
prevention in developing countries.
Clin
Lab Med
2004;24:945-963.
30. Guidozzi F. Obstet screening for cervical
cancer.
Gynecol Surv
1996;51:247-252.
31. Anderson GH, Boyes DA, Benedet JL,
et al. Organisation and results of cervi-
cal cytology screening programme in
British Columbia, 1955-1985.
BMJ
1988;296:975-978.
32. Collaco LM, de Noronha L, Pinheiro DL,
et al. Quality assurance in cervical screen-
ing of a high risk population: a study of
65,753 reviewed cases in Parana Screen-
ing Program, Brazil.
Diagn Cytopathol
2005;33:441-448.
33. Sankaranarayanan R, Thara S, Sharma A,
et al. Accuracy of conventional cytology:
Results from a multicentre screening
study in India.
J Med Screen
2004;11:
77-84.
34. Sankaranarayanan R, Gaffikin TL, Jacob M
et al. A critical assessment of screening
methods for cervical neoplasia.
Int J
Gynaecol Obstet
2005;89(suppl 2):S4-S12.
35. Zeferino LC, Derchain SF. Cervical cancer
in the developing world. Best practice
research.
Clin Obstet Gynec
2006;20:
339-354.
36. Marcus AC, Crane LA, Kaplan CP, et al.
Improving adherence to screening follow-
up among women with abnormal Pap
smears: results from a large clinic-based
trial of three intervention strategies.
Med
Care
1992;30:216-230.
37. Garner D. Potencial limitations of screen-
ing programs.
Task Force 13. International
Consensus Conference on the Fight against
Cervical Cancer.
International Academy of
Cytology. 2000.
38. Kirnbauer R, Booy F, Cheng N, et al.
Papillomavirus L1 major capsid protein
self-assembles into virus-like particles
that are highly immunogenic.
Proc Natl
Acad Sci USA
1992;89:12,180-12,184.
39. Harro CD, Pang YY, Roden RB, et al.
Safety and immunogenicity trial in adult
volunteers of a human papillomavirus
16 L1 virus-like particle vaccine.
J Natl
Cancer Inst
2001;93:284-292.
40. Koutsky LA, Ault KA, Wheeler CM, et al.
A controlled trial of a human papillo-
mavirus type 16 vaccine.
N Engl J Med
2002;347:1645-1651.
41. Harper DM, Franco EL, Wheeler C, et al.
Efficacy of a bivalent L1 virus-like particle
vaccine in prevention of infection with
human papillomavirus types 16 and 18
in young women: a randomised control-
led trial.
Lancet
2004;364:1757-1765.
42. Villa LL, Costa RL, Petta CA, et al. Prophy-
lactic quadrivalent human papillomavi-
rus (types 6, 11, 16, and 18) L1 virus-like
particle vaccine in young women: a rand-
omized double-blind placebo controlled
multicentre phase II efficacy trial.
Lancet
Oncol
2005;6:271-278.
43. Munoz N, Bosch FX, Castellsagué X, et al.
Against which human papillomavirus
types shall we vaccinate and screen? The
international perspective.
Inter J Cancer
2004;111:278-285.
44. WHO. Report of the consultation on
human papillomavirus vaccines. 2005;
Geneva; 1-34. Acessed on 2007 Mar 31.
Available from: http://www.who.int/
vaccines-documents/DocsPDF05/
816screen.pdf
45. Parry J. Vaccinating against cervical can-
cer.
Bull World Health Organ
2007;85(2).
46. Harper DM, Franco EL, Wheeler C, et al.
Sustained efficacy up to 4-5 years of a
bivalent L1 virus-like particle vaccine
against human papillomavirus types 16
and 18: follow-up from a randomised
control trial.
Lancet
2006;367:
1247-1255.
47. Pollack AE, Balkin M, Edouard L, et al.
Ensuring access to HPV vaccines through
integrated services: a reproductive health
perspective.
Bull World Health Organ
2007;85(1).
48. Goldie SJ, Kohli M, Grima D, et al.
Projected clinical benefits and cost-
effectiveness of a human papillomavirus
16/18 vaccine.
J Natl Cancer Inst
2004;96:604-615.
49. Wright TC,Jr, Cox JT, Massad LS. 2001
consensus guidelines for the manage-
ment of women with cervical intraepi-
thelial neoplasia.
Am J Obstet Gynecol
2003;1:295-304.
50. Bosch FX: Cervical cancer epidemiology
and rationale for human papilomavi-
rus (HPV) related preventive strategies.
Twenty-first International Conference
and Clinical Workshop Papilomavirus
,
2004.
51. Franco EL, Ferenckzy A. Is HPV testing
with cytological triage a more logical
approach in cervical cancer screening?
Lancet Oncol
2006;7:527-529.
52. Girianelli VR, Thuler LC, Szklo M, et
al. Comparison of human papilloma-
virus DNA tests, liquid-based cytology
and conventional cytology for the early
detection of cervix uteri cancer.
Eur J Cancer Prev
2006;15:504-510.
53. Diehl IS, Prado R, Magna RM. Organiza-
cion Panamericana de la Salud. Manual
de Procedimientos del Laboratorio de
Citologia. Red Panamericana de
Citologia y Tamizaje. Red-PAC. 2002;
1-84.
54. World Health Organization. Screening
and early detection of cancer. Accessed on
2007 Mar 31. Available from: http://www.
who.int/cancer/detection/en/
55. Gondos B, King EB. Significance of
endometrial cells in cervicovaginal
smears.
Ann Clin Lab Sci
1977;7(6):
486-490.
56. Smith RA, von Eschenbach AC, Wender
R, et al. American Cancer Society guide-
lines for the early detection of cancer:
update of early detection guidelines for
prostate, colorectal, and endometrial
cancers. Also: update 2001—testing for
early lung cancer detection.
CA Cancer J
Clin
2001;51:38-75.
57. Fontana RS, Sanderson DR, Woolner LB,
et al. Screening for lung cancer. A cri-
tique of the Mayo Lung Project.
Cancer
1991;67(4 Suppl):1155-1164.
58. Petty TL. The early identification of
lung carcinoma by sputum cytology.
Cancer
2000;89(11 Suppl):2461-
2464.
56
previous page 61 ComprehensiveCytopathology 1104p 2008 read online next page 63 ComprehensiveCytopathology 1104p 2008 read online Home Toggle text on/off